0001515768-14-000003.txt : 20140403
0001515768-14-000003.hdr.sgml : 20140403
20140403151901
ACCESSION NUMBER: 0001515768-14-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20140403
DATE AS OF CHANGE: 20140403
EFFECTIVENESS DATE: 20140403
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ABATTIS BIOCEUTICALS CORP
CENTRAL INDEX KEY: 0001515768
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-214864
FILM NUMBER: 14741894
BUSINESS ADDRESS:
STREET 1: SUITE 1000 - 355 BURRARD STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 2G8
BUSINESS PHONE: 604-538-6650
MAIL ADDRESS:
STREET 1: SUITE 1000 - 355 BURRARD STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6C 2G8
FORMER COMPANY:
FORMER CONFORMED NAME: ABATTIS BIOLOGIX Corp
DATE OF NAME CHANGE: 20110316
D
1
primary_doc.xml
X0707
D
LIVE
0001515768
ABATTIS BIOCEUTICALS CORP
SUITE 1000 - 355 BURRARD STREET
VANCOUVER
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
604-538-6650
BRITISH COLUMBIA, CANADA
ABATTIS BIOLOGIX Corp
Corporation
true
Mike
Withrow
SUITE 1000 - 355 BURRARD STREET
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
Executive Officer
Director
Tim
Fealey
SUITE 1000 - 355 BURRARD STREET
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
Director
Douglas
J.
Sorocco
SUITE 1000 - 355 BURRARD STREET
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
Director
Robert
Hedley
SUITE 1000 - 355 BURRARD STREET
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
Director
Rene
David
SUITE 1000 - 355 BURRARD STREET
Vancouver
A1
BRITISH COLUMBIA, CANADA
V6C 2G8
Executive Officer
Other Health Care
$1 - $1,000,000
- 06b
false
2014-03-18
true
true
true
true
true
Each unit is comprised of one common share and one share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.50 for a period of eighteen months, subject to acceleration.
false
0
2489145
83709
2405436
The additional $2,405,436 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on March 18, 2014, which was Cdn$1.1086=US$1.00.
false
6
0
0
0
In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.
false
ABATTIS BIOCEUTICALS CORP
/s/ Mike Withrow
Mike Withrow
Chief Executive Officer and President
2014-04-01